<DOC>
	<DOCNO>NCT02761512</DOCNO>
	<brief_summary>To demonstrate non-inferiority CJ-12420 lansoprazole 30 mg capsule term therapeutic efficacy , confirm safety CJ-12420 , daily oral administration CJ-12420 50 mg , 100 mg Lansoprazole 30 mg capsule gastric ulcer patient .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy CJ-12420 Patients With Gastric Ulcer</brief_title>
	<detailed_description>This double blind , randomize , placebo-controlled , phase 3 study . Subjects randomly assign one three treatment group ( CJ-12420 50 mg , 100 mg Lansoprazole 30 mg ) .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<criteria>1 . Diagnosis 1 active gastric ulcer ( ≥3 mm ~ ≤30 mm use open biopsy forceps ) accord SakitaMiwa classification ( A1 A2 stage ) upper GI endoscopy institution within 14 day prior initiation investigational product administration . 1 . Finding gastrointestinal bleeding , esophageal stricture , ulcer stenosis , pyloric stenosis , esophageal gastric varix , Barrett 's esophageal &gt; 3 cm ( long segment Barrett esophagus , LSBE ) , duodenal ulcer , intractable ulcer , digestive ulcer perforation malignancy upper GI endoscopy . 2 . Ulcer cause endoscopic surgery ( e.g. , ulcer EMR/ESD ) 3 . Requirement persistent daily use drug may cause ulcer nonsteroidal antiinflammatory drug ( NSAIDs ) aspirin course study 4 . Scheduled surgery require hospitalization requirement surgical treatment study participation 5 . Subjects participate clinical trial within 4 week prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>